Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between “nice to know” and “need to know” pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.
Document Type
Article
Publication Date
3-2014
Digital Object Identifier (DOI)
http://dx.doi.org/ 10.1038/clpt.2013.221
Repository Citation
Crettol, Séverine; de Leon, Jose; Hiemke, Christoph; and Eap, Chin B., "Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine" (2014). Psychiatry Faculty Publications. 19.
https://uknowledge.uky.edu/psychiatry_facpub/19
Notes/Citation Information
Published in Clinical Pharmacology & Therapeutics, v. 95, issue 3, p. 254-257.
This is the peer reviewed version of the following article: Crettol, S., de Leon, J., Hiemke, C. and Eap, C. B. (2014), Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine. Clinical Pharmacology & Therapeutics, 95: 254–257., which has been published in final form at http://dx.doi.org/ 10.1038/clpt.2013.221 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.